All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Multiple Myeloma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View multiple myeloma content recommended for you

IMS congress 2022

Share:

Aug 25, 2022

X post image

13 Apr 2023

Catch up with this!
#IMS2022 | Want to know more about the efficacy and safety of ABBV-383, a BCMA/CD3 bispecific antibody, for the treatment of patients with #RRMM?
Read about the findings from a phase I study here.
👉 https://t.co/ySHNbDmc3r
#MMsm

X post image

23 Nov 2022

#IMS2022 | Want to know more about the efficacy and safety of ABBV-383, a BCMA/CD3 bispecific antibody, for the treatment of patients with #RRMM?
Read about the latest findings from a phase I study here.
👉 https://t.co/ySHNbDmc3r
#MMsm

X post image

11 Nov 2022

#IMS2022 | @SurbhiSidanaMD discussed the current outlook on QoL for patients with #multiplemyeloma after CAR T-cell therapy, highlighting the effects of financial toxicity and strategies to improve QoL.
Read our summary here 👉 https://t.co/JvCFMab3vh
#myeloma #MMsm

X post image

13 Oct 2022

#IMS2022 | Mezigdomide + bortezomib and dexamethasone showed an efficacy of 81.6% in a dose escalation phase I/II trial in patients with RRMM. The most common TEAEs were neutropenia, infections, and thrombocytopenia.
Read more in our article 👉 https://t.co/AZKYHK4OsS
#mmsm

X post image

3 Oct 2022

🎧 During the #IMS2022 Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Roman Hájek, University of Ostrava, CZ. We asked, Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?

#mmsm

https://t.co/cnCGrgxUgF

X post image

16 Sept 2022

🎥 During the 19th #IMS2022 Annual Meeting, the Multiple Myeloma Hub was pleased to speak to María-Victoria Mateos. We asked, Is it possible to use different B-cell maturation antigen (BCMA)-targeted agents successively? #mmsm @mvmateos https://t.co/W3VRsk3LZO

X post image

28 Aug 2022

We hope you enjoyed following our live updates and congress coverage!

We covered #IMS2022 from Los Angeles and virtually.

Keep an eye on our socials for post-congress key points and insights! 📲

#medicalcongress #multiplemyeloma

X post image

28 Aug 2022

#IMS2022 | @SurbhiSidanaMD continued highlightening the effects of financial toxicity with #CARTcells and listing what can be done to improve #QoL pre and post-treatment #mmsm

X post image

28 Aug 2022

#IMS2022 | Fantastic presentation by @SurbhiSidanaMD on #QoL after #CARTcell infusion. With both approved agents, there was an initial drop at the same time of higher symptom burden, and a progressive improvement after, reaching baseline status, although that was still poor #mmsm

X post image

28 Aug 2022

#IMS2022 | Regarding immunosuppression and risk of infections, @YiLinMDPhD conducted a survey within the participants of this meeting and shared the results. Of note, the majority of respondents would consider IVIG without the presence of recurrent or severe infections.#mmsm

X post image

28 Aug 2022

#IMS2022 | @YiLinMDPhD reviews the practical management of short and long-term toxicities with #CARTcell therapies in #myeloma #mmsm

X post image

27 Aug 2022

#IMS2022 | @Mohty_EBMT highlights the reported median PFS of 75.3 months with a frontline regimen that is now all available in its generic versions #mmsm

X post image

27 Aug 2022

#IMS2022 | Results of the GEM2012 trial of MEL200 vs BUMEL with an intesified VRd induction and consolidation, presented by Joan Blade #mmsm

X post image

27 Aug 2022

#IMS2022 | Great to see the initial experiences with novel #CARTcell therapies in real-world. Doris Hansen shares the data of ide-cel, including patients who were previously exposed to BCMA-directed therapies #mmsm

🎥 Watch our interview from #ASCO22: https://t.co/8KpQeAu8Jw

X post image

27 Aug 2022

RT @Mohty_EBMT: Mechanisms of resistance to bispecifics. A lot is yet to be done! #ims2022 ⁦@Myeloma_Society⁩

X post image

27 Aug 2022

#IMS2022 | Douglas Sborov @MyelomaSLC presents the final analysis of the GRIFFIN trial of Dara + RVd vs RVd, and adding daratumumab also in consolidation and maintenance therapy. Ph III data are awaited to definitely confirm the role of quadruplets in frontline tx #mmsm

X post image

27 Aug 2022

#IMS2022 | @TomBmt133 shares some insights on the latest immunotherapies for #myeloma.
Great summary slide on #bispecific antibodies!
#mmsm

X post image

27 Aug 2022

#IMS2022 | ABBV-383 has a dual binding to BCMA and is designed to evade systemic T-cell activation; but still 72% of patients experienced some Grade of CRS at the 60mg dose level, although mostly G1-2. #mmsm

X post image

27 Aug 2022

#IMS2022 | Peter Voorhees @LevineCancer shares the FIH results of the BCMA-directed #bispecific antibody ABBV-383 (TNB-383B). Administered every 3 weeks, this new agent achieves an ORR >50% in the subgroups studied, including triple-refractory #mmsm

X post image

27 Aug 2022

RT @Myeloma_Society: Congratulations to this year's Young Investigator Award recipients at #IMS2022.

X post image

27 Aug 2022

RT @BrunoPaiva_UNAV: Amazing to have an immune reconstitution and vaccination session at the #IMS2022. This will be a major research area!…

X post image

27 Aug 2022

It’s the last day of IMS! 👏

Don’t miss out on our final live updates.

Closing interviews, key insights, and congress coverage.

Session covered:
- New data and expert discussions on cell therapy for multiple myeloma

#IMS2022 #medicalcongress #multiplemyeloma

X post image

27 Aug 2022

RT @HiraSMian: Dr Nooka presenting on options available in the relapsed setting, exciting and hopeful time in MM @AjayNookaMD #IMS2022 http…

X post image

27 Aug 2022

#IMS2022 | The OS curve of patients with R/R #myeloma after progressing to BCMA CAR T-cell therapy shows a clear unmet need on effective therapeutic alternatives for this population #mmsm

X post image

27 Aug 2022

#IMS2022 | Kevin Reyes presents the @UCSFCancer experience treating patients who relapsed after a BCMA #CARTcell. Limited sample size but showing promising data of patients responding to subsequent BCMA-directed agents #mmsm

X post image

27 Aug 2022

#IMS2022 | @HangQuach1 presents the interim analysis of belamaf + Kd in the first 10 patients treated. Despite the small numbers, investigators are encouraged by the responses seen in daratumumab and PI-exposed patients #mmsm

X post image

27 Aug 2022

#IMS2022 | The phase II part of REGN5458 is moving forward recruiting patients after the initial results presented by Naresh Bumma #bispecific #mmsm
Read more here: https://t.co/s9aM0TwsFZ

X post image

26 Aug 2022

CONGRESS #IMS2022 | Roman Hajek presents long-term depth of response data from the IKEMA trial of Isa-Kd vs Kd, for the treatment of relapsed #MM. The results show a clinically meaningful improvement in depth of response for Isa-Kd.

@Myeloma_Society

#medicalcongress #mmsm

X post image

26 Aug 2022

Congratulations @mvmateos on receiving the Bart Barlogie Clinical Investigator Award!🏅We are honored to have you as a Co-Chair of the Multiple Myeloma Hub #IMS2022 #mmsm

X post image

26 Aug 2022

CONGRESS #IMS2022 | Paul Richardson @DanaFarber @harvardmed presents data on the combination therapies MeziVd, MeziVd-1.0mg and MeziKd, for the treatment of R/R #MM. Both MeziVd and MeziKD demonstrated an acceptable safety profile and promising efficacy.

#medicalcongress #mmsm

X post image

26 Aug 2022

CONGRESS #IMS2022 | Paul Richardson @DanaFarber @harvardmed presents data on final OS analysis of the phase III ICARIA-MM trial of Isa+Pd vs Pd in patients with R/R #MM. The results demonstrate a clinically meaningful benefit and manageable safety profile for Isa-Pd treatment.

X post image

26 Aug 2022

CONGRESS #IMS2022 | María-Victoria Mateos, MD PhD addresses unmet needs and future directions for #myeloma therapy. NDMM remains a substantial unmet need in this area.

#medicalcongress #mmsm

X post image

26 Aug 2022

CONGRESS #IMS2022 | Thierry Facon, @CHU_Lille discusses key abstracts and their impact on #myeloma therapy.

X post image

26 Aug 2022

CONGRESS #IMS2022 | Paul Richardson @DanaFarber @harvardmed reports data on the phase III DETERMINATION trial of RVd ± ASCT with R maintenance to progression in patients with newly diagnosed #MM.

RVd+ASCT offers improved PFS vs RVd-alone (82.2 vs 53.2 months)

#medicalcongress

X post image

26 Aug 2022

CONGRESS #IMS2022 | Claudia Stege, @amsterdamumc discusses current treatment paradigms and future perspectives for elderly and frail patients with #myeloma. Further investigations into SOC and frailty adapted treatment protocols are needed going forward.

#medicalcongress #mmsm

X post image

26 Aug 2022

NEWS 🚨
The European Commission has granted conditional marketing authorization to teclistamab 💉 as monotherapy for the treatment of adult patients with RRMM.
Read more 👉 https://t.co/hseep078Qh
#mmsm #RRMM #MedNews #IMS2022

X post image

26 Aug 2022

The Multiple Myeloma Hub will be bringing you comprehensive updates as we continue our live coverage.📖

Sessions covered:
- Induction for newly diagnosed myeloma
- Relapsed multiple myeloma

#medicalcongress #multiplemyeloma #IMS2022

X post image

26 Aug 2022

Fantastic start of the #IMS2022! It really makes a difference when a conference prioritizes and blocks time for abstract Q&A and panel discussions!👏👏@Myeloma_Society #mmsm

X post image

26 Aug 2022

#IMS2022 | Great final presentation on future questions and unmet needs in high-risk #myeloma by @MyMKaiser.
Important note about putting the patient first when bringing molecular risk assessment to clinical practice
#PatientCenteredCare #mmsm

X post image

26 Aug 2022

RT @paurotero: Redefining high-risk MM. Excellent talk by Jill Corre at #IMS2022.

X post image

26 Aug 2022

#IMS2022 | @AjaiChari brings up the importance of continuous assessment of risk beyond R-ISS. Other key clinical variables like early relapse or drug refractoriness define a ‘functional HR disease’ that should be considered for treatment decisions, trial design and analysis #mmsm

X post image

26 Aug 2022

CONGRESS #IMS2022 | Shaji Kumar @myelomaMD highlights that to see an improvement in outcomes of high-risk #MM, the focus should be on depth of response and duration. See below his recommendations for TE and TNE #mmsm

X post image

25 Aug 2022

CONGRESS #IMS2022 | @BrunoPaiva_UNAV, @ClinicaNavarra discusses immune reconstitution as a means of monitoring immune dysfunction and predicting outcome in patients with #myeloma. It may serve as a cost-effective, standardized and predictive biomarker.

#medicalcongress #mmsm

X post image

25 Aug 2022

CONGRESS #IMS2022 | @szusmani, @MSKCancerCenter discusses some key abstracts in context and addresses important questions on disease monitoring.

@Myeloma_Society

#medicalcongress #mmsm #myeloma

X post image

25 Aug 2022

CONGRESS #IMS2022 | Noemí Puig from @usal speaks on the application of mass spectrometry methods to #myeloma diagnosis and disease monitoring.

@Myeloma_Society

#medicalcongress #mmsm

X post image

25 Aug 2022

CONGRESS #IMS2022 | @BrunoPaiva_UNAV, @ClinicaNavarra presents data from the phase II KarMMa study showing that patients who achieve early and sustained undetectable MRD after treatment with ide-cel have prolonged PFS.

@Myeloma_Society
#medcongress #mmsm #CARTcell #celltherapy

X post image

25 Aug 2022

CONGRESS #IMS2022 | @TomBmt133, @USSanDiego speaks on the depth of MRD assessment in the context of #multiplemyeloma. MRD negativity can provide an excellent biomarker for PFS and OS.

@Myeloma_Society

#medicalcongress #mmsm

X post image

25 Aug 2022

IMS starts today! 🔔

The Multiple Myeloma Hub is covering IMS virtually and in person.

The following sessions will be covered today:
- Disease monitoring
- Myeloma clinical challenges
- High-risk myeloma

#IMS2022 #medicalcongress #multiplemyeloma

X post image

23 Aug 2022

The Multiple Myeloma Hub is covering the 19th International @Myeloma_Society (IMS) Annual Meeting!

Date: August 25–27
Location: LA, California

Keep an eye on our socials for live coverage from our virtual and in-person attendance!🗣💻

#IMS2022 #medicalcongress #multiplemyeloma

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

IMS 2022 Relapsed/refractory multiple myeloma Newly diagnosed multiple myeloma Plasma cell dyscrasias International Myeloma Society

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Newsletter

Subscribe to get the best content delivered to your inbox